NYSE:AZN', 'AstraZeneca PLC', 'http://weeklyregister.com/weekly-register-logo.png');

Does Astrazeneca Plc (NYSE:AZN) Have Gas After Even Less Sellers Involved?

December 7, 2017 - By reb123z

 Does Astrazeneca Plc (NYSE:AZN) Have Gas After Even Less Sellers Involved?

The stock of Astrazeneca Plc (NYSE:AZN) registered a decrease of 11.84% in short interest. AZN’s total short interest was 14.88M shares in December as published by FINRA. Its down 11.84% from 16.88M shares, reported previously. With 3.58 million shares average volume, it will take short sellers 4 days to cover their AZN’s short positions. The short interest to Astrazeneca Plc’s float is 0.6%.

The stock increased 0.41% or $0.13 during the last trading session, reaching $32.22. About 3.48M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since December 7, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $78.65 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 21.13 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, November 25 by Liberum Capital. The stock of AstraZeneca PLC (NYSE:AZN) has “Hold” rating given on Monday, April 10 by Jefferies. The rating was maintained by Leerink Swann with “Market Perform” on Monday, October 23. Leerink Swann maintained the stock with “Market Perform” rating in Monday, May 2 report. The stock of AstraZeneca PLC (NYSE:AZN) has “Buy” rating given on Wednesday, August 9 by Piper Jaffray. The firm earned “Neutral” rating on Wednesday, April 5 by UBS. Bernstein upgraded the shares of AZN in report on Friday, September 22 to “Outperform” rating. The stock of AstraZeneca PLC (NYSE:AZN) has “Buy” rating given on Monday, September 14 by Deutsche Bank. The stock of AstraZeneca PLC (NYSE:AZN) has “Underperform” rating given on Tuesday, October 20 by Credit Suisse. The company was downgraded on Friday, July 28 by Morgan Stanley.

More important recent AstraZeneca PLC (NYSE:AZN) news were published by: Marketwatch.com which released: “AstraZeneca: FDA grants Imfinzi priority review” on October 17, 2017, also Investorplace.com published article titled: “AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success”, Investorplace.com published: “Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc. (AMD) and Spirit …” on July 27, 2017. More interesting news about AstraZeneca PLC (NYSE:AZN) was released by: Investorplace.com and their article: “AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment” with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.